fig3
From: Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Figure 3. Response to ICIs according to Response Evaluation Criteria in Solid Tumors guidelines 1.1 (RECIST 1.1): (A) response to ICIs across molecular alterations; (B) response rate by treatment modality in EGFR patients; and (C) response rate by treatment modality in EGFR patients. ICIs: Immune checkpoint blockades; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; WT: wild type. EGFR: epidermal growth factor receptor; KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog.
